|
TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. |
|
|
Consulting or Advisory Role - Tesaro |
|
|
Consulting or Advisory Role - AstraZeneca; Genentech; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Bristol-Myers Squibb; Eisai; Eisai; Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Honoraria - Amgen; NanoString Technologies; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Genomic Health; Helsinn Therapeutics; Pfizer; Spectrum Pharmaceuticals; Tesaro |
|
|
Speakers' Bureau - Genentech |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Abbvie |
Research Funding - Abbvie (Inst); Advaxis (Inst); Bayer/Onyx (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - Caris Centers of Excellence; Caris Life Sciences |
|
Andrea Elisabeth Wahner Hendrickson |
No Relationships to Disclose |
|
|
Speakers' Bureau - Seagen |
Research Funding - Tesaro |
Patents, Royalties, Other Intellectual Property - Jones Bartlett; UpToDate |
|
|
Consulting or Advisory Role - Angiochem; Genentech/Roche; Kadmon; Lilly; Merrimack; Nektar; Novartis; Sanofi; to-BBB technologies BV |
Research Funding - Angiochem (Inst); Cascadian Therapeutics (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tesaro (Inst); to-BBB technologies BV (Inst) |
Patents, Royalties, Other Intellectual Property - Jones and Bartlell; Up to Date.com |
|
|
Research Funding - Merck (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb; Pfizer |
|
|
Honoraria - Perceptive Informatics; Revere Pharmaceuticals |
Consulting or Advisory Role - Revere Pharmaceuticals |
|
|
Stock and Other Ownership Interests - Express Scripts; Merck |
Consulting or Advisory Role - Tesaro |
|
|
|
Stock and Other Ownership Interests - Tesaro |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Tesaro |
|
|
|
Stock and Other Ownership Interests - Medtronic; Tesaro |
|
|
|
Stock and Other Ownership Interests - Tesaro |
|
|
Consulting or Advisory Role - AstraZeneca; Celldex; Pfizer; PharmaMar; Tesaro; Vertex |
Research Funding - Abbvie (Inst); Biothera (Inst); Calithera Biosciences (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); OncoSec (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst); Vertex (Inst) |
Other Relationship - G1 Therapeutics |